Abstract
With the explosive development of nanotechnology, engineered nanomaterials are currently being used in various industries, including food and medicine. Concern about the health effects of nanomaterials has been raised, and available research indicates that the relative surface area of nanomaterials seems to correlate with the severity of their toxicity. With regard to engineered nanomaterials, the scope of their acute and chronic toxicities and their mechanisms are not fully understood. Studies suggest that exposure to certain nanomaterials can generate reactive oxidant species and enhance permeability of the phagolysosomal membrane, which leads to inflammasome activation, causing oxidative stress and inflammation. Since the latter 2 are implicated in the development of cardiovascular diseases, such as hypertension and atherosclerosis, it can be presumed that exposure to engineered nanomaterials could significantly impact cardiovascular function. In this review, I raise issues that should be considered in the assessment of the effects of engineered nanomaterials on cardiovascular function, and evaluate their cardiovascular toxicity as described in various in vitro and/or in vivo toxicological studies and industrial investigations.